Pubblicazioni Scientifiche Anno 2011 - Azienda Ospedaliera Santi ...

prognosis in Mds high-risk patients treated with 5-Azacitidine” - EHA –Londra 9-12 giugno 2011, Haematologica 2011; 96: 44418. Agostinelli C., Gallamini A., Rigacci L., Vitolo U., Stracqualursi L.,Piccaluga P., Stelitano C., Patti C., Argnani L., Broccoli A., Levis A.,D’Amore F., Zinzani P., Pileri S.A. “The prognostic value of biologicmarkers in Classical Hodgkin Lymphoma (CHL) patients” - 11 thInternational Conference on Malignant Lymphoma – Lugano 18-21 giugno2011, Annals of Oncology 2011; 22 (suppl. 4)19. Balzarotti M., Brusamolino E., Massidda S., Pulsioni A., Carella A.M.,Vitolo U., Spina M., Merli F., Levis A., Re A., Rusconi C., Stelitano C.,Cascavilla N., Gaidano G., Zinzani P.L., Santoro A. “IGEV Vs. IGEV+Bortezomib (Velcade Tm) before highdose consolidation therapy followedby Autologous Stem Cell Transplantation (ASCT) in relapsed or refractoryHodgkin Lymphoma (Hl): a randomized phase II trial of the FondazioneItaliana Linfomi” - 11 th International Conference on Malignant Lymphoma– Lugano 18-21 giugno 2011, Annals of Oncology 2011; 22 (suppl. 4)20. Benedetto B., Passera R., Patriarca F., Bonifazi F., Montefusco V., FaldaM., Giaccone L., Montanari M., Bacigalupo A., Guidi S., Mordini N.,Rambaldi A., Milone G., Carella A.M., Bavaro P., Ciceri F., Scimè R.,Benedetti E., Levis A., Marenco P., Casini M., Bosi A., Corradini P.,Bandini G., Fanin R., Boccadoro M. and Pollichieni S. “Allogeneic bonemarrow transplantation from unrelated donors in multiple myeloma: astudy from the Italian Bone Marrow Transplantation Donor Registry” –ASH – San Diego, California 10-13 dicembre 2011, sessione poster21. Cilloni D., Messa E., Biale L., Bonferroni M., Salvi F., Lunghi M., AllioneB., Ferrero D., Freilone R., Levis A. and Saglio G. “High rate of erythroidresponse during iron chelation therapy in a cohort of 105 patients affectedby hematologic malignancies with transfusional iron overload: an italianmulticenter retrospective study” - ASH – San Diego, California 10-13dicembre 2011, comunicazione orale22. Corradini P., Sarina B., Carniti C., Patriarca F., Carella A.M., Levis A.,Bosi A., Falda M., Di Bartolomeo P., Olivares C., Gimondi S., VendraminA. and Dodero A. “High-dose rituximab in the conditioning regimen beforeallogeneic stem cell transplantation reduces the incidence of acute GVHDin B-Cell lymphomas” - ASH – San Diego, California 10-13 dicembre2011, sessione poster23. Corradini P., Sarina B., Patriarca F., Carella A., Levis A., Bosi A., FaldaM., Di Bartolomeo P., Olivares C., Dodero A. “High-dose rituximab in theconditioning regimen before allogeneic stem cell transplantation reducesthe incidence of acute Gvhd in B-cell lymphomas” - EHA – Londra 9-12giugno 2011, Haematologica 2011; 96: 23324. Forconi F., Zaja F., Intermesoli T., Stelitano C., Cantaffa R., Pulsoni A.,Zinzani P.L., Gerlinzoni F., Levis A., Martinelli G., Galieni P., Rossi D.,Rigacci L., Gallamini A., Pileri S.A., Lauria F. “Cladribine givensubcutaneously for five days has equivalent efficacy to and lower toxicitythan cladribine given for seven consecutive days in patients with hairy cellleukaemia” – 11 th International Conference on Malignant Lymphoma –Lugano 18-21 giugno 2011, Annals of Oncology 2011; 22 (suppl. 4)25. Greenberg P., Tuechler H., Schanz J., Sole F., Bennett J.M., Garcia-Manero G., Levis A., Malcovati L., Cazzola M., Sanz G., Cermak J.,Fonatschll C., LeBeau M., Slovak M., Kriegerl O., Luebbert M.,Magalhaes S., Miyazakj Y., Pfeilstocker M., Sekeres M., Maciejewski J.,Stauder R., Tauro S., Van de Loosdrecht A., Germing U., Fenaux P., HaaseD. “Revised International Prognostic Scoring System (IPSS-R). Developedby the International Prognostic Working Group For Prognosis In Mds(IWG-PM)” – MDS Edinburgo 18-21 magio 2011, Leukemia Research2011; 35: 5626. Intermesoli T., Rossi G., Delfini F., Romani C., Pogliani E., Pagani C.,Angelucci E., Terrazzi E., Levis A., Cassibba V., Mattei D., GianfaldoniG., Scattolin A.M., Di Bona E., Parolini M., Rambaldi A., Bassan R. “Curerates and toxicity vary according to age < vs. > 55 years N B·All andBurkitt lymphoma treated with the german chemotherapy plus rituximab14